Adding orelabrutinib and teniposide to standard drugs for newly diagnosed brain lymphoma
Original title: Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a mid to late stage study, but it is still a test.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests whether adding one or two extra drugs to standard treatment helps people newly diagnosed with a lymphoma in the brain.
Who this trial is for. This trial is for people who were just diagnosed with primary CNS lymphoma, a cancer in the brain. It compares three drug plans, and which one a person gets is decided by chance.
Where it stands. The trial has not reported results. All three plans include rituximab, methotrexate, and dexamethasone. One plan adds orelabrutinib. One adds both orelabrutinib and teniposide. The trial is looking at how well the cancer responds to each plan. People whose cancer clears go on to more treatment, which may include more drugs, a stem cell transplant, or a lower dose of radiation to the whole brain. Which plan works best is not known yet.
What this means, and what it doesn't
What it could mean: If you or someone you care for was just diagnosed with this kind of brain lymphoma, this study may be worth asking about. Your care team can tell you whether it fits your situation.
What it doesn't mean: This does not mean the extra drugs work. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that you will do better. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 18, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.